Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

On Wednesday, Hutchmed (China) Limited (NASDAQ: ​HCM) reported 2024 earnings of 22 cents per ADS or 4 cents per share, down 59 cents or 12 cents a year ago. Sales fell 25% year over year to $630.20 million.

Fruzaqla’s revenue was $110.8 million, and Elunate’s sales reached $86.3 million.

Oncology product consolidated revenue increased 65% to $271.5 million, driven by Fruzaqla and exceeding 30% to 50% growth guidance.

Guidance: Hutchmed projects 2025 oncology/immunology consolidated revenue of $350 million–$450 million.

On Tuesday, Hutchmed (China) and Innovent Biologics, Inc. announced topline results from FRUSICA-2 Phase 2/3 trial of fruquintinib in combination with ...